sec61al1 Antibody

What is SEC61A1 and what cellular processes is it involved in?

SEC61A1 is the α-subunit of the Sec61 complex, which plays a crucial role in endoplasmic reticulum (ER) protein transport and passive calcium leakage . The Sec61 complex functions as the central component of the protein translocation apparatus of the ER membrane, essentially serving as a channel through which newly synthesized proteins enter the ER lumen or get integrated into the ER membrane . Beyond protein translocation, SEC61A1 also contributes to ER calcium homeostasis by functioning as a passive calcium leak channel . Recent research has implicated SEC61A1 mutations in several diseases, including autosomal dominant severe congenital neutropenia (SCN), common variable immunodeficiency, and glomerulocystic kidney disease .

What experimental applications are validated for SEC61A1 antibodies?

SEC61A1 antibodies have been validated for multiple experimental applications:

Different antibodies may have specific validation profiles. For example, the SEC61A1 (D4K2Z) Rabbit mAb from Cell Signaling Technology is validated specifically for Western Blot and Immunoprecipitation applications , while other antibodies may have broader application profiles . Always verify the validation status for your specific experimental needs.

What species reactivity should be considered when selecting a SEC61A1 antibody?

When selecting a SEC61A1 antibody, consider the species you're working with and verify the antibody's validated reactivity. Based on the available data:

It's worth noting that while SEC61A1 is highly conserved across species, epitope differences can affect antibody performance. Always check if the antibody has been validated in your specific experimental system. If working with less common model organisms, epitope conservation analysis may be required before antibody selection .

How should SEC61A1 antibodies be stored to maintain activity?

Proper storage is critical for maintaining antibody activity. For SEC61A1 antibodies:

• Store at -20°C for long-term stability

• Most formulations remain stable for one year after shipment when properly stored

• The common storage buffer is PBS with 0.02% sodium azide and 50% glycerol at pH 7.3

• Aliquoting is generally unnecessary for -20°C storage, but may be advisable for frequently used antibodies to prevent freeze-thaw cycles

• Some antibody preparations (particularly in small volumes like 20μl) may contain 0.1% BSA as a stabilizer

Always consult the manufacturer's specific recommendations, as formulations may vary between providers.

What are the optimal protocols for detecting SEC61A1 in studies of ER stress and the unfolded protein response (UPR)?

When studying the relationship between SEC61A1 and ER stress or UPR, several methodological considerations are crucial:

First, Western blotting using SEC61A1 antibodies can be combined with UPR markers such as phosphorylated eIF2α, CHOP (CCAAT/enhancer-binding protein homologous protein), and BiP (Immunoglobulin heavy chain binding protein) . The optimal approach involves analyzing both SEC61A1 expression/localization and these UPR markers simultaneously.

For experiments assessing SEC61A1's role in ER stress:

• Use validated SEC61A1 antibody dilutions (typically 1:1000 for Western blotting)

• Include appropriate UPR marker antibodies

• Employ treatments that induce ER stress (e.g., tunicamycin, thapsigargin)

• Compare wild-type cells with SEC61A1-mutated or SEC61A1-deficient cells

Research has shown that CRISPR/Cas9 genome editing of SEC61A1 in THP-1 cells suppressed mycolactone-induced endoplasmic reticulum stress, particularly eIF2α phosphorylation . This model system can be adapted to study how SEC61A1 disruption affects various components of the UPR pathway.

Quantitative PCR for UPR genes provides another valuable approach, as demonstrated in studies of SEC61A1 mutations in severe congenital neutropenia, where UPR gene expression was assessed to understand the mechanism of disrupted myeloid differentiation .

What controls should be included when using SEC61A1 antibodies to study protein translocation defects?

When investigating protein translocation defects using SEC61A1 antibodies, rigorous controls are essential:

• Positive controls: Include cell lines known to express SEC61A1 at detectable levels (HEK-293, HeLa, HepG2, L02 cells, mouse/rat liver tissue) .

• Negative controls:

  • Primary antibody omission

  • SEC61A1 knockdown/knockout cells (if available)

  • Non-specific IgG from the same species as the primary antibody

• Experimental controls:

  • Compare wild-type SEC61A1 with mutant variants (e.g., the Q92R mutation identified in congenital neutropenia)

  • Include reporter proteins known to be dependent on SEC61A1 for translocation

  • Monitor unrelated proteins that don't use the SEC61 complex for proper controls

• Fractionation controls: When separating subcellular fractions, include markers for each compartment (e.g., calnexin for ER, GAPDH for cytosol).

• Loading controls: Standard loading controls (β-actin, GAPDH) should be included for Western blotting.

For advanced studies, consider protein translocation assays where SEC61A1 function can be directly assessed using in vitro translation systems supplemented with ER membranes, followed by protease protection assays to determine translocation efficiency.

How can SEC61A1 antibodies be employed to study calcium homeostasis disruption?

SEC61A1 functions as a passive calcium leak channel in the ER membrane, making it an important target in calcium homeostasis studies. Methodological approaches include:

• Co-localization studies: Use SEC61A1 antibodies (1:50-1:500 dilution) for immunofluorescence in combination with calcium-binding proteins (e.g., calreticulin) to examine spatial relationships at the ER membrane .

• Calcium flux assays: These can be performed in systems with wild-type versus mutant SEC61A1, as certain mutations may affect calcium leakage function. Previous studies have shown that specific SEC61A1 mutations result in increased calcium leakage from the ER .

• Live cell calcium imaging: Combined with SEC61A1 knockdown/overexpression to assess the functional contribution of SEC61A1 to calcium dynamics.

• Subcellular fractionation: Use SEC61A1 antibodies to confirm the purity of ER fractions before calcium content analysis.

• Proximity ligation assays: To identify interactions between SEC61A1 and calcium regulatory proteins.

When designing such experiments, consider that SEC61A1's role in calcium homeostasis may be modulated by interactions with other proteins or affected by specific mutations that alter channel properties rather than protein expression levels. Therefore, functional assays should complement expression analyses.

What methodological approaches are recommended for investigating SEC61A1 mutations in disease models?

Recent research has linked SEC61A1 mutations to several diseases, including severe congenital neutropenia, common variable immunodeficiency, and glomerulocystic kidney disease . When investigating these disease-associated mutations:

• Mutation verification and characterization:

  • For genomic analysis, design specific primers for SEC61A1 (e.g., 5′-GCCTGGCGTTGAATTGGTG-3′ and 5′-AAGTGTGAGGGGCTACTCAA-3′)

  • Perform direct sequencing to confirm mutations

• Protein expression and stability analysis:

  • Western blotting using SEC61A1 antibodies (1:1000 dilution) to compare wild-type and mutant protein levels

  • Pulse-chase experiments to assess protein half-life

• Functional assays:

  • In vitro differentiation of CD34+ cells to recapitulate neutrophil maturation defects observed in patients

  • Cell line models (e.g., HL-60 cells) can be used to validate the impact of mutations on differentiation into specific cell types

• UPR activation assessment:

  • qPCR for UPR genes in cells expressing wild-type versus mutant SEC61A1

  • Single-cell RNA sequencing on primary samples (e.g., bone marrow) to identify cell type-specific perturbations in UPR

• Rescue experiments:

  • Complementation with wild-type SEC61A1 in mutant backgrounds

  • Pharmacological interventions targeting UPR or calcium homeostasis

For example, research on the SEC61A1 c.A275G;p.Q92R mutation in congenital neutropenia has demonstrated protein expression reduction, disturbed protein translocation, increased calcium leakage from the ER, and dysregulation of the UPR in myeloid precursors .

What strategies can resolve non-specific binding or background issues when using SEC61A1 antibodies?

When encountering non-specific binding or high background with SEC61A1 antibodies:

• Antibody titration: Test a range of dilutions to find the optimal concentration. For Western blotting, SEC61A1 antibodies have been tested at dilutions from 1:2000 to 1:12000 .

• Blocking optimization:

  • Test different blocking agents (BSA, non-fat dry milk, commercial blockers)

  • Increase blocking time (1-2 hours at room temperature or overnight at 4°C)

  • Add 0.1-0.3% Tween-20 to reduce non-specific hydrophobic interactions

• Antigen retrieval for IHC:

  • For SEC61A1 detection in tissue samples, both TE buffer (pH 9.0) and citrate buffer (pH 6.0) have been recommended for antigen retrieval

  • Optimize retrieval time and temperature

• Secondary antibody considerations:

  • Use highly cross-adsorbed secondary antibodies

  • Reduce secondary antibody concentration

  • Include 1-5% serum from the host species of the secondary antibody in the diluent

• Sample preparation:

  • Ensure proper cell lysis and protein denaturation

  • Consider membrane enrichment protocols for better detection of this transmembrane protein

For immunofluorescence applications, additional washing steps with PBS containing 0.1% Triton X-100 can help reduce background while maintaining specific signal.

How can SEC61A1 antibody performance be validated in CRISPR/Cas9 edited cell models?

CRISPR/Cas9 gene editing provides powerful tools for SEC61A1 antibody validation and functional studies:

• Validation of antibody specificity:

  • Create SEC61A1 knockout cell lines using CRISPR/Cas9

  • Compare antibody signal between wild-type and knockout cells via Western blot

  • Complete signal loss in knockout cells confirms specificity

• Partial knockdown controls:

  • Generate heterozygous knockout cells

  • Verify reduced signal intensity correlating with gene dosage

• Validation methodology:

  • Design specific sgRNAs targeting SEC61A1 (previous studies have successfully targeted this gene)

  • Verify editing by genomic PCR and sequencing

  • Confirm protein reduction/loss by Western blotting

• Considerations for essential genes:

  • Complete SEC61A1 knockout may be lethal in some cell types

  • Consider inducible CRISPR systems or partial knockdown approaches

  • Target specific domains rather than complete gene knockout

• Rescue experiments:

  • Re-express SEC61A1 in knockout cells to restore antibody signal

  • Include epitope-tagged versions to distinguish endogenous from exogenous protein

For example, in previous studies, researchers validated CRISPR/Cas9 editing of SEC61A1 by extracting genomic DNA, performing PCR amplification of the target site, and confirming modifications through both gel electrophoresis and direct sequencing .

What are the key considerations when using SEC61A1 antibodies for co-immunoprecipitation studies?

Co-immunoprecipitation (Co-IP) with SEC61A1 antibodies requires careful optimization:

• Antibody selection:

  • Choose antibodies validated for immunoprecipitation (IP)

  • Recommended amounts: 0.5-4.0 μg for 1.0-3.0 mg of total protein lysate

  • Consider the location of the epitope (N-terminal, C-terminal, internal) as it may affect protein complex interactions

• Lysis conditions:

  • Use mild non-ionic detergents (0.5-1% NP-40, Triton X-100, or digitonin)

  • Include protease inhibitors and phosphatase inhibitors if studying phosphorylation states

  • Maintain physiological salt concentration to preserve protein-protein interactions

• Preclearing:

  • Preclear lysates with protein A/G beads to reduce non-specific binding

  • Include isotype control antibodies in parallel experiments

• IP controls:

  • Input control: 5-10% of the lysate used for IP

  • IgG control: Non-specific IgG from the same species

  • Reverse IP: Immunoprecipitate with antibodies against suspected interaction partners

• Elution strategies:

  • Consider native elution with peptide competition if available

  • Standard SDS elution may disrupt some interactions

• Verification methods:

  • Confirm successful IP by probing for SEC61A1 first

  • Then probe for suspected interaction partners

  • Consider mass spectrometry for unbiased identification of interaction partners

When investigating SEC61A1 interactions, it's important to note that this protein is part of a complex (with SEC61B and SEC61G) and interacts with various translocation-associated proteins. The membrane-bound nature of SEC61A1 (with multiple transmembrane domains) means that standard IP protocols may need to be adapted for optimal results.

How can SEC61A1 antibodies be utilized to investigate its role in disease pathogenesis?

SEC61A1 has been implicated in several diseases including severe congenital neutropenia, common variable immunodeficiency, and tubulointerstitial kidney disease . Antibody-based approaches to study its role in pathogenesis include:

• Expression analysis in patient samples:

  • Compare SEC61A1 protein levels in affected versus healthy tissues

  • Use immunohistochemistry (1:50-1:500 dilution) to examine tissue distribution patterns

  • Correlate expression levels with disease severity or stage

• Mutation impact studies:

  • Generate cell models expressing disease-associated mutations (e.g., Q92R mutation in neutropenia)

  • Use SEC61A1 antibodies to assess protein stability, localization, and function

  • Compare wild-type and mutant protein interactions with key pathway components

• Mechanistic investigations:

  • Employ single-cell RNA sequencing combined with protein analysis to identify cell populations with perturbed UPR

  • Use in vitro differentiation assays with primary CD34+ cells to model neutrophil maturation defects

  • Analyze calcium flux in cells expressing wild-type versus mutant SEC61A1

• Therapeutic target validation:

  • Use antibodies to monitor SEC61A1 levels following experimental treatments

  • Assess normalization of downstream pathways (e.g., UPR, calcium homeostasis)

  • Employ proximity ligation assays to assess restoration of normal protein interactions

In the context of congenital neutropenia, research has shown that specific SEC61A1 mutations disrupt neutrophil maturation by dysregulating the unfolded protein response. This connection was validated through both patient sample analysis and in vitro modeling systems .

What considerations are important when using SEC61A1 antibodies in high-throughput screening applications?

When adapting SEC61A1 antibodies for high-throughput screening applications:

• Assay miniaturization:

  • Optimize antibody concentrations specifically for higher-throughput formats

  • Validate signal-to-noise ratios in the miniaturized format

  • Establish Z-factor values >0.5 to ensure assay robustness

• Automation compatibility:

  • Select antibody formulations compatible with automated liquid handlers

  • Consider stability at room temperature during automated processing

  • Validate performance in presence of common additives used in automated systems

• Readout selection:

  • For fluorescence-based detection, verify lack of interference with screening compounds

  • Consider using SEC61A1 antibodies in high-content imaging systems to simultaneously assess localization and expression

  • Alphascreen/HTRF approaches may provide higher sensitivity for protein-protein interaction studies

• Controls and normalization:

  • Include both positive controls (known modulators of SEC61A1 or its pathway)

  • Include negative controls on each plate

  • Use internal references for normalization across plates

• Validation strategy:

  • Confirm primary hits with orthogonal assays

  • Use different antibody clones for validation to eliminate epitope-specific artifacts

  • Include dose-response follow-up for promising candidates

These approaches are particularly relevant when screening for compounds that might rescue SEC61A1 mutation-induced defects in disease models or when identifying modulators of SEC61A1-dependent pathways.

How do different SEC61A1 antibody clones compare in performance across applications?

When selecting between different SEC61A1 antibody clones, consider these comparative factors:

For specific research questions:

• Western blotting for protein quantification: Both monoclonal (e.g., D4K2Z) and polyclonal antibodies perform well, with recommended dilutions of 1:1000-1:12000

• Immunoprecipitation: Antibody selection depends on the experimental goal; some clones are specifically validated for this application

• Microscopy applications: Consider antibodies validated for IF/ICC with appropriate dilutions (1:50-1:500)

Always validate the selected antibody in your specific experimental system, regardless of published performance data.

What are the challenges in detecting SEC61A1 in different subcellular compartments?

SEC61A1 is primarily localized to the ER membrane, but detecting it in different cellular contexts presents unique challenges:

• Membrane protein detection challenges:

  • SEC61A1 has multiple transmembrane domains, requiring careful sample preparation

  • Complete denaturation is essential for Western blot detection

  • Consider membrane enrichment protocols for low abundance detection

• Fixation considerations for microscopy:

  • Different fixation methods (paraformaldehyde vs. methanol) may affect epitope accessibility

  • Permeabilization must be optimized for accessing ER membrane proteins

  • Mild detergents (0.1-0.3% Triton X-100 or 0.1% saponin) are typically effective

• Co-localization studies:

  • When examining SEC61A1 interactions with other proteins, super-resolution microscopy may be necessary

  • Include established ER markers (calnexin, PDI) as positive controls

  • Consider proximity ligation assays for detecting closely associated proteins

• Dynamic localization:

  • Under stress conditions, SEC61A1 distribution may change

  • Live-cell imaging with fluorescently tagged SEC61A1 can complement antibody-based detection

  • Compare resting and stimulated conditions (e.g., UPR induction)

• Tissue-specific considerations:

  • Different tissues may require specific antigen retrieval methods

  • SEC61A1 has been successfully detected in liver tissue, pancreas tissue, and various cell lines

  • Antibody performance may vary between tissue types

Optimizing these parameters ensures accurate detection of SEC61A1 across different subcellular compartments and experimental conditions.